Evaluation of tamoxifen and simvastatin as the combination therapy for the treatment of hormonal dependent breast cancer cells

Tamoxifen (TAM) is a nonsteroidal antiestrogen drug, used in the prevention and treatment of all stages of hormone-responsive breast cancer. Simvastatin (SIM), a lipid-lowering agent, has been shown to inhibit cancer cell growth. The study aimed at investigating the impact of using SIM with TAM in e...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Toxicol Rep
Päätekijät: Ibrahim, Amel B., Zaki, Hala F., Ibrahim, Walaa W., Omran, Mervat M., Shouman, Samia A.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Elsevier 2019
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6880098/
https://ncbi.nlm.nih.gov/pubmed/31788433
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.toxrep.2019.10.016
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia